CD28 and glioma: Anti-EGFRvIII CAR-T cells were also the subject of a study by Abott et al. who created second-generation CAR-T cells with an scFv showing high affinity for EGFRvIII and with a CD28 co-stimulatory domain and tested their ability to kill glioma cells in vitro and in vivo.